REFERENCES
- Autoimmune hemolytic anemia. In: Orkin SH, Nathan DG, Ginsburg D, Look AT, eds. Hematology of Infancy and Childhood. 7th ed. Philadelphia: WB Sanders; 2009:618–632.
- Dacie J. The immune hemolytic anemia's: a century of exciting progress in understanding. Br Hematol. 2001;114:770–785.
- Ramanathan S, Koutts J, Hertzberg MS. Two cases of refractory warm autoimmune hemolytic anemia treated with rituximab. Am J Hematol. 2005;78:123–126.
- Arena GD, Califano C, Annunziata M, Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients compilation. European Journal of Hematology 2007;79:53–58.
- Zecca M, De Stefano P, Nobili B, Locatelli F. Anti-CD20 monoclonal antibody for the treatment of severe immune-mediated pure red cell aplasia and hemolytic anemia. Blood. 2001;97:3995–3997.
- Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin Proc. 2003;78:1340–1346.
- Zecca M, Nobili B, Ramenghi U, Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood. 2003;101:3857–3861.
- Ouartier P, Brethon B, Philippet P, Treatment of childhood autoimmune hemolytic anemia with rituximab. Lancet. 2001;358:1511–1513.
- Stasi R, Pagano A, Stipa E, Amatori S. Rituximab chimeric anti CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98:952–957.